West Pharmaceutical Services (WST) reported Q4 adjusted earnings Thursday of $1.82 per diluted share, down from $1.83 a year earlier.
Analysts polled by FactSet expected $1.72.
Revenue for the quarter ended Dec. 31 was $748.8 million compared with $732 million a year earlier.
Analysts surveyed by FactSet expected $740 million.
The company said it expects 2025 adjusted-diluted EPS to range from $6 to $6.20. Analysts surveyed by FactSet expect $7.45. The company expects revenue for the year to be $2.88 billion to $2.91 billion. Analysts polled by FactSet expect $3.04 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.